Article Versions Notes

Bonizzi A, Truffi M, Sevieri M, Allevi R, Sitia L, Ottria R, Sorrentino L, Sottani C, Negri S, Grignani E, et al. Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines. Pharmaceutics. 2019; 11(8):384. https://doi.org/10.3390/pharmaceutics11080384

Bonizzi, Arianna, Marta Truffi, Marta Sevieri, Raffaele Allevi, Leopoldo Sitia, Roberta Ottria, Luca Sorrentino, Cristina Sottani, Sara Negri, Elena Grignani, and et al. 2019. "Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines" Pharmaceutics 11, no. 8: 384. https://doi.org/10.3390/pharmaceutics11080384

Bonizzi, A., Truffi, M., Sevieri, M., Allevi, R., Sitia, L., Ottria, R., Sorrentino, L., Sottani, C., Negri, S., Grignani, E., Mazzucchelli, S., & Corsi, F. (2019). Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines. Pharmaceutics, 11(8), 384. https://doi.org/10.3390/pharmaceutics11080384